NanoViricides, Inc. (NYSE American: NNVC) announced it has applied to the Democratic Republic of Congo’s regulatory agency for approval to initiate a Phase II clinical trial evaluating its NV-387 Oral Gummies as a treatment for the current Bundibugyo ebolavirus outbreak. The company retained Om Sai Clinical Research Private Limited as the contract research organization, with drug supplies already in the DRC.
NV-387 is an orally administered broad-spectrum antiviral designed to target host-side mechanisms that viruses rely on to infect cells, which the company believes may reduce the likelihood of viral resistance. The planned study builds on NanoViricides’ ongoing Phase II Mpox trial in the DRC and comes as the company seeks to address an outbreak that, according to the release, has resulted in more than 930 deaths and nearly 2,400 confirmed cases since May.
The company said it believes NV-387’s oral formulation could offer logistical advantages over infusion-based therapies in resource-limited settings and, if successful, could support development of a broad-spectrum treatment for Ebola and other filoviruses. This development is significant because it represents a potential shift toward more accessible antiviral treatments in outbreak regions where infrastructure challenges often hinder intravenous therapies.
The full press release is available at https://ibn.fm/tmrCX. For more information about NanoViricides, visit https://www.nanoviricides.com.
